Category: Biosimilars
United States Biosimilars
-
United States Generic Drugs Market Assessment, By Application [Neurovascular, Cardiovascular, Dermatology, Oncology, Diabetology, Respiratory, Others], By Type [Biosimilar Generics, Small Molecule Generics], By Brand [Branded Generic, Pure Generic], By Route of Administration [Oral, Injectable, Topical, Others], By Distribution Channel [Hospital Pharmacy, Retail Pharmacy, Online Pharmacy], By Region, Opportunities and Forecast, 2017-2031F
... Others], By Distribution Channel [Hospital Pharmacy, Retail Pharmacy, Online Pharmacy], By Region, Opportunities and Forecast, 2017-2031F United States generic drugs market is projected to witness a CAGR of 6.68% during the forecast period 2024-2031, growing ... Read More
-
Plunkett's Biotech, Pharmaceuticals & Genetics Industry Almanac 2025: Biotech, Pharmaceuticals & Genetics Industry Market Research, Statistics, Trends and Leading Companies
... vital insights that can help shape strategy for business development, product development and investments. Key Features: Business trends analysis In-depth industry overview Technology trends analysis Forecasts Spending, investment, and consumption discussions In-depth industry statistics and ... Read More
-
US Biosimilar Market: Insights & Forecast with Potential Impact of COVID- 19 (2024-2028)
... spanning from 2024 to 2028. Growth in the US biosimilar market is supported by factors such as rising prevalence of cancer, growing geriatric population and favorable environment. However, the market growth is expected to be ... Read More
-
2024 United States Biosimilars Forecast (2025-2030 Outlook)-Market Opportunities Report
... The market is expected to increase from USD xx billion in 2025 to USD xx billion by 2030, at a CAGR of xx% from 2025 to 2030. Estimates on product and service sales are published ... Read More
-
Biosimilars: US Payer Perspectives
... Will adalimumab biosimilars and the anticipated launch of biosimilar Stelara in 2025 be the catalysts to drive meaningful healthcare savings? What factors influence payers’ adoption and support of biosimilars? Companies AbbVie, Amgen, Novartis, Teva, Pfizer, ... Read More
-
US Pharmaceutical Market Size and Forecast (2020 - 2030), Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product (Vaccines, Biologics & Biosimilars, and Small Molecules)
... grow from US$ 846.72 billion in 2022 to US$ 1,285.79 billion by 2030, estimated to grow at a CAGR of 5.36% from 2022 to 2030. The US pharmaceutical market growth in the US pharmaceutical market ... Read More
-
United States Generic Drugs Market By Type (Small Molecule Generics, Biosimilars), By Application (Cardiovascular Diseases, Diabetes, Neurology, Oncology, Infectious Diseases, Others), By Mode of Drug Delivery (Oral, Topical, Parenteral, Others), By Form (Tablet, Capsule, Injection, Others), By Source (In House, Contract Manufacturing Organizations), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), By Region, Competition, Forecast and& Opportunities, 2018-2028F
... Others), By Source (In House, Contract Manufacturing Organizations), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), By Region, Competition, Forecast and& Opportunities, 2018-2028F United States Generic Drugs Market has valued at USD 104.23 ... Read More
-
North America Human Insulin Drugs Market - By Product (Human Insulin, Basal Insulin, Bolus Insulin, Insulin Combinations, Biosimilar Insulins); By Application (Product I Diabetes, Product II Diabetes); By Country (United States, Canada), Trend Analysis, Competitive Landscape & Forecast, 2019–2029
... Landscape & Forecast, 2019–2029 North America Human Insulin Drugs Market Size Grows Steadily to Touch USD 10.3 Billion by 2029 North America human insulin drugs market is flourishing because of an increasing prevalence of type ... Read More
-
US Public Health Spending on Biosimilars: a data driven analysis
... and patients. By the end of 2020, the FDA had approved 29 biosimilar products for eight different original biologic products. Of these, 18 had been launched by the end of that year with many more ... Read More
-
Biosimilars: US Payer Insights
... US biosimilar sector development. But is that about to change? Will the launch of biosimilar adalimumab re-invigorate the sector? How is the Inflation Reduction Act impacting biosimilars? Why is it critical for developers to educate ... Read More
-
United States Human Insulin Market, By Product Type (Human Insulin Drugs, Human Insulin Delivery Devices); By Type (Insulin Analogs and Biosimilars, Human Insulin Biologics); By Delivery Devices (Syringes, Pens, Pen Needles); By Application (Type I Diabetes, Type II Diabetes); By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)Trend Analysis, Competitive Market Share & Forecast, 2018-2028
... Diabetes, Type II Diabetes); By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)Trend Analysis, Competitive Market Share & Forecast, 2018-2028 United States Human Insulin Market to Grow at a CAGR of 4.1% during 2022-2028 The ... Read More
Research Assistance
